Raymond James & Associates’s Avidity Biosciences RNAM Stock Holding History

Raymond James & Associates’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$7.2M	Buy	156,763 +3,131	+2%	+$136K	﹤0.01%	1412
2024 Q2	$6.28M	Sell	153,632 -142,086	-48%	-$4.08M	﹤0.01%	1430
2024 Q1	$7.55M	Buy	295,718 +165,797	+128%	+$2.6M	0.01%	1316
2023 Q4	$1.18M	Buy	129,921 +36,666	+39%	+$245K	﹤0.01%	2427
2023 Q3	$595K	Buy	93,255 +9,815	+12%	+$84.6K	﹤0.01%	2782
2023 Q2	$925K	Buy	83,440 +68,160	+446%	+$855K	﹤0.01%	2524
2023 Q1	$235K	Sell	15,280 -6,333	-29%	-$139K	﹤0.01%	3406
2022 Q4	$480K	Buy	+21,613	New	+$322K	﹤0.01%	2922
2021 Q2	–	Sell	-49,643	Closed	-$1.08M	–	4186
2021 Q1	$1.08M	Buy	+49,643	New	+$1.22M	﹤0.01%	2453

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's RNAM Position: Q3 2024 in Review

Raymond James & Associates increased its Avidity Biosciences (RNAM) stake by 2% in Q3 2024, buying an estimated $136K and bringing the position to 156,763 shares worth $7.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Raymond James & Associates first reported a position in RNAM in Q1 2021 and has held it in 9 quarters since. The position peaked at $7.55M in Q1 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

Raymond James & Associates held 156,763 shares of Avidity Biosciences worth $7.2M as of Q3 2024.
Raymond James & Associates bought 3,131 Avidity Biosciences shares in Q3 2024, an estimated $136K.
Avidity Biosciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1412 holding.
Raymond James & Associates first reported a position in Avidity Biosciences in Q1 2021 and has held it in 9 quarters since.
Raymond James & Associates's Avidity Biosciences position peaked at $7.55M in Q1 2024.
245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.